Present and Future of Dyslipidaemia Treatment—A Review
Journal of Clinical Medicine · 08.09.2023 · 12 (18) · 5839
DOI: 10.3390/jcm12185839 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 08.09.2023. Verfasst von Iveta Merćep und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 123 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
One of the greatest burdens on the healthcare systems of modern civilization is cardiovascular diseases (CVDs). Therefore, the medical community is looking for ways to reduce the incidence of CVDs. Simple lifestyle changes from an unhealthy to a healthy lifestyle are the cornerstone of prevention, but other risk factors for cardiovascular disease are also being currently targeted, most notably dyslipidaemia. It is well known that lowering serum lipid levels, and in particular lowering elevated LDL-cholesterol, leads to a reduction in major cardiovascular events. Although the focus to date has been on LDL-cholesterol levels and lowering them with statin therapy, this is often not enough because of increased concentrations of other lipoprotein particles in the serum and residual cardiovascular risk. Since lowering LDL-cholesterol levels is successful in most cases, there has been a recent focus on lowering residual cardiovascular risk. In recent years, new therapeutic options have emerged that target triglyceride-rich lipoproteins, lipoprotein (a) and apolipoproteins C and B. The effects of these drugs on serious adverse cardiovascular events are not yet known, but recent studies with some of these drugs have shown significant results in lowering total lipid levels. The aim of this review is to present the current therapeutic options for the treatment of dyslipidaemia and to describe the newly approved drugs as well as the drugs that are still in development. Although at this stage we cannot say with certainty whether these agents will be approved and widely used, it is safe to say that our views on the treatment of dyslipidaemia are certainly changing.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
- Division of Clinical Pharmacology, Department of Internal Medicine, University Hospital Centre Zagreb, 10000 Zagreb, Croatia.
- Department of Ophthalmology, Sestre Milosrdnice University Hospital Centre, 10000 Zagreb, Croatia.
- Division of Metabolic Diseases, Department of Internal Medicine, University Hospital Centre Zagreb, 10000 Zagreb, Croatia.
- Department of Cardiology and Congenital Diseases of Adults, Polish Mother's Memorial Hospital Research Institute, 93-338 Lodz, Poland.
ORCID-Profile: Iveta Merćep, Dominik Strikić
Zitieren
APA
Merćep, I., Vujević, A., Strikić, D., Radman, I., Pećin, I., & Reiner, Ž. (2023). Present and Future of Dyslipidaemia Treatment—A Review. Journal of Clinical Medicine, 12(18), 5839. https://doi.org/10.3390/jcm12185839
Vancouver
Merćep I, Vujević A, Strikić D, Radman I, Pećin I, Reiner Ž. Present and Future of Dyslipidaemia Treatment—A Review. Journal of Clinical Medicine. 2023;12(18):5839. doi:10.3390/jcm12185839
BibTeX
@article{Merep2023,
author = {Merćep, Iveta and Vujević, Andro and Strikić, Dominik and Radman, Ivana and Pećin, Ivan and Reiner, Željko},
title = {Present and Future of Dyslipidaemia Treatment—A Review},
journal = {Journal of Clinical Medicine},
year = {2023},
volume = {12},
number = {18},
pages = {5839},
doi = {10.3390/jcm12185839}
}
EUVIMED